- Tel: 858.663.9055
-
Email: info@nsjbio.com
- Tel: 858.663.9055
- Email: info@nsjbio.com
Related Products
|
DR5 Antibody DR5/3381 / TNFRSF10B Monoclonal Antibody targets death receptor 5 (DR5), a transmembrane protein encoded by the TNFRSF10B gene. Also known as TRAIL receptor 2 (TRAILR2), CD262, and KILLER, DR5 belongs to the tumor necrosis factor receptor superfamily and participates in the regulation of programmed cell death. It binds tumor necrosis factor-related apoptosis-inducing ligand (TRAIL, also called TNFSF10), which can activate the extrinsic apoptotic pathway. DR5 is distinguished from TRAIL decoy receptors by its functional intracellular death domain, which enables the recruitment of signaling proteins required for apoptosis.
DR5 contains extracellular cysteine-rich domains involved in ligand binding, a single transmembrane region, and a cytoplasmic death domain. Binding of TRAIL promotes receptor clustering and assembly of a death-inducing signaling complex (DISC). This complex recruits the adaptor protein FADD and initiator procaspases, particularly procaspase-8, leading to caspase activation. Activated caspase-8 can directly stimulate executioner caspases or cleave BID to engage mitochondrial apoptotic signaling. The resulting cascade promotes the controlled dismantling of cells through programmed cell death.
DR5 signaling is influenced by receptor abundance, intracellular trafficking, post-translational modifications, and the availability of regulatory proteins. Depending on cellular context, TRAIL receptor engagement can also activate non-apoptotic pathways involving NF-kappaB, MAP kinases, and inflammatory signaling. Expression of TNFRSF10B is regulated by several transcriptional mechanisms, including responses to cellular stress and the tumor suppressor p53. These regulatory interactions connect DR5 activity with DNA damage responses, cellular homeostasis, and the elimination of damaged or abnormal cells.
DR5 has attracted considerable attention in cancer biology because TRAIL-mediated apoptosis can contribute to the elimination of malignant cells. However, resistance to TRAIL signaling may arise through altered receptor expression, defective caspase activation, or increased activity of anti-apoptotic proteins. DR5 Antibody DR5/3381 provides a means of investigating TNFRSF10B expression in relation to death receptor signaling, tumor biology, and mechanisms governing cellular sensitivity to apoptosis.
DR5 is an important regulator of apoptosis and a focus of cancer research investigating tumor-cell survival, TRAIL signaling, and resistance to programmed cell death.
Optimal dilution of the DR5 Antibody DR5/3381 / TNFRSF10B Monoclonal Antibody should be determined by the researcher.
A recombinant protein partial protein (amino acids 266-393) was used as the immunogen for this DR5 antibody.
Store the DR5 antibody at 2-8oC (with azide) or aliquot and store at -20oC or colder (without azide).
Death receptor 5 antibody, TRAIL receptor 2 antibody, TRAILR2 antibody, TRAIL R2 antibody, CD262 antibody, KILLER antibody, TNF receptor superfamily member 10B antibody, Tumor necrosis factor receptor superfamily member 10B antibody, TRICK2 antibody, TRICK2A antibody, TRICK2B antibody, DR5 protein antibody
Your bulk quote request has been submitted successfully!
Please contact us if you have any questions.